CYCN News and Press, Cyclerion Therapeutics Inc. From 06/15/21

4 Reddit Penny Stocks For Your June Watchlist Finding penny stocks on Reddit has become a favored pastime for many investors. While it can be challenging, investing in penny stocks can also be a profitable endeavor. There are a few ways to ensure your best chance at seeing your port...

3 Meme Penny Stocks For Your June Watchlist Meme penny stocks are here to stay. While it began as more or less of a joke, these small-caps have become extremely popular among all types of investors. But before we get into what they are, let’s talk about penny stocks . When in...

Gainers: Clover Health Investments CLOV +70%, Precipio PRPO +15%, GBS (GBS) +15%, PDS Biotechnology PDSB +15%, Cyclerion Therapeutics CYCN +10%.Losers: Ra Medical Systems RMED -19%, HOOKIPA Pharma HOOK -15%, AC Immune (ACIU...

Cyclerion Therapeutics (CYCN) has added ~14.3% in early hours after the company disclosed a string of insider purchases yesterday.In transactions dated June 03, CEO Peter M Hecht, director, Terrance Mcguire, and top institutional shareholder, Slate Path Capital have made combined pu...

Clover Health Investments (CLOV) +37%.Aytu Biopharma (AYTU) +20%.NextDecade Corporation NEXT +20% after Morgan Stanley upgrades on Rio Grande LNG outlook.Cyclerion Therapeutics (CYCN) +16%.The Wendy's (WEN) +16%.Stitch Fix SFIX +14% on Q3 results.PDS Biotechnology PDS...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We’re starting off our coverage today with a look at the biggest pre-market stock movers for Tuesday. Source: Eric Urquhart/Shutterstock.com Before we get to that, let’s take a m...

Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, and tiered sales-based royalties Praliciguat out-licensing further enables Cyclerion’s strategic focus on CNS, including first-in-class CNS-penetrant sGC st...

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) --  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced a direct private sale of approximately $18 million of Cycleri...

Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator Oral, once-daily CY6463 is being developed for neurological diseases associated with cognitive impairment CAMBRIDGE, Mass., May 2...

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET. Management will also be available...